Euroapi (XPAR:EAPI) 5-Year Sharpe Ratio: N/A (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:EAPI Euroapi SA XPAR:EAPI
58 GF Score
Price €0.98
GF Value €2.87
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Euroapi 5-Year Sharpe Ratio?

The 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. As of today (2026-07-31), Euroapi's 5-Year Sharpe Ratio is Not available.


Euroapi  (XPAR:EAPI) 5-Year Sharpe Ratio Explanation

The 5-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past five years. It is calculated as the annualized result of the average five-year monthly excess returns divided by its standard deviation in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Euroapi 5-Year Sharpe Ratio Related Terms


XPAR:EAPI vs ZTS, UTHR, VTRS: 5-Year Sharpe Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Euroapi's 5-Year Sharpe Ratio, along with its competitors' market caps and 5-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Euroapi 5-Year Sharpe Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Euroapi's 5-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Euroapi's 5-Year Sharpe Ratio falls into.


XPAR:EAPI
58GF Score
Euroapi SA XPAR:EAPI
5-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Euroapi 5-Year Sharpe Ratio Calculation

The 5-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last five years. A stock / portfolio's 5-Year Sharpe Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past five years.

Is Euroapi (XPAR:EAPI) Overvalued in 2026?

Based on GuruFocus' analysis, Euroapi stock appears to be undervalued. The current stock price of €0.98 is trading 65.9% below its estimated GF Value™ of €2.87. GuruFocus considers Euroapi to be Possible Value Trap.

Key valuation signals for XPAR:EAPI:

  • 5-Year Sharpe Ratio: N/A
  • GF Value™: €2.87 vs. price of €0.98 (65.9% below fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the XPAR:EAPI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Euroapi Business Description

Other Exchanges EAPIF:USA0EAP:UK940:Germany
Address 32 rue Alexandre Duma, Paris, FRA, 75011
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates, analgesics, and others. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers.
58GF Score

Get the complete analysis for XPAR:EAPI

5-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.98
Price
€2.87
GF Value